Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
| ▸ | CD74 | P04233 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469620 | 0.88 | KIT (0.64) | KITFLT3NTRK3JAK2MAPK10 | |
| SCHEMBL21153067 | 0.79 | FLT3 (0.56) | KITFLT3NTRK3ST14 | |
| SCHEMBL21153073 | 0.79 | FLT3 (0.56) | KITFLT3NTRK3ST14 | |
| SCHEMBL17469789 | 0.77 | KIT (0.52) | KITFLT3NTRK3ST14NPC1 | |
| SCHEMBL18999173 | 0.73 | KIT (0.64) | KITFLT3NTRK3ABL1ST14 | |
| SCHEMBL17469650 | 0.66 | FLT3 (0.75) | KITFLT3NTRK3ST14NPC1 | |
| SCHEMBL17469652 | 0.66 | KIT (0.75) | KITFLT3NTRK3ST14NPC1 | |
| SCHEMBL17469649 | 0.66 | KIT (1.00) | KITFLT3NTRK3ST14NPC1 | |
| SCHEMBL17469648 | 0.66 | KIT (0.75) | KITFLT3NTRK3ST14NPC1 | |
| SCHEMBL21152053 | 0.66 | KIT (0.44) | KITFLT3NTRK3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | KIT 2616/4885FLT3 2354/4885NTRK3 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.